Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = trapping system for HCV

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 6064 KiB  
Article
Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus
by Dmitry Polyakov, Ekaterina Sinitsyna, Natalia Grudinina, Mariia Antipchik, Rodion Sakhabeev, Viktor Korzhikov-Vlakh, Mikhail Shavlovsky, Evgenia Korzhikova-Vlakh and Tatiana Tennikova
Pharmaceutics 2021, 13(5), 672; https://doi.org/10.3390/pharmaceutics13050672 - 7 May 2021
Cited by 11 | Viewed by 2420
Abstract
Hepatitis C is one of the most common social diseases in the world. The improvements in both the early diagnostics of the hepatitis C and the treatment of acute viremia caused by hepatitis C virus are undoubtedly an urgent task. In present work, [...] Read more.
Hepatitis C is one of the most common social diseases in the world. The improvements in both the early diagnostics of the hepatitis C and the treatment of acute viremia caused by hepatitis C virus are undoubtedly an urgent task. In present work, we offered the micro- and nanotraps for the capturing of HCV. As a capturing moiety, we designed and synthesized in E. coli a fusion protein consisting of large extracellular loop of CD81 receptor and streptavidin as spacing part. The obtained protein has been immobilized on the surface of PLA-based micro- and nanoparticles. The developed trapping systems were characterized in terms of their physico-chemical properties. In order to illustrate the ability of developed micro- and nanotraps to bind HCV, E2 core protein of HCV was synthesized as a fusion protein with GFP. Interaction of E2 protein and hepatitis C virus-mimicking particles with the developed trapping systems were testified by several methods. Full article
(This article belongs to the Special Issue Advances in Delivering Protein and Peptide Therapeutics)
Show Figures

Figure 1

Back to TopTop